ID
21502
Description
NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Non-serious Adverse Events Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV
Keywords
Versions (1)
- 4/25/17 4/25/17 -
Uploaded on
April 25, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Genetic Screening For HLA-B*5701 in Patients with HIV Non-serious Adverse Events NCT00340080
Genetic Screening For HLA-B*5701 Non-serious Adverse Events NCT00340080
Similar models
Genetic Screening For HLA-B*5701 Non-serious Adverse Events NCT00340080
C1518404 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C1518404 (UMLS CUI [2])
C1518404 (UMLS CUI [2])
C1518404 (UMLS CUI [1,2])